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ABSTRACT
Objective: Patients with rheumatoid arthritis (RA) are
at increased risk of cardiovascular (CV) disease and
are also commonly prescribed non-selective non-
steroidal anti-inﬂammatory drugs (ns-NSAIDs). New in
vitro evidence suggests that this increased CV risk may
be mediated through aldosterone glucuronidation
inhibition (AGI), which differs between NSAIDs
(diclofenac>naproxen>indomethacin>ibuprofen).
Our aim was to explore the association between
ns-NSAID-related AGI and arterial dysfunction.
Methods: The extent (augmentation index, AIX%) and
timing (reﬂected wave transit time, RWT, ms) of aortic
wave reﬂection (measured using radial applanation
pulse wave analysis, PWA, SphygmoCor device) were
assessed on a single occasion in 114 consecutive RA
patients without overt CV disease aged 40e65 years.
A higher AIX% and lower RWT indicate arterial
dysfunction. Assessment included a fasting blood
sample, patient questionnaire and medical record
review. Multivariate analysis was used to adjust for
age, sex, mean blood pressure, smoking, cumulative
erythrocyte sedimentation rate (ESR-years) and
Stanford disability score.
Results: We identiﬁed 60 patients taking ns-NSAIDs
and 25 non-users. Using a ns-NSAID with the highest
AGI was associated with a higher AIX% (and lower
RWT) versus treatment with a ns-NSAID with the
lowest AGI (diclofenac AIX% 32.3, RWT 132.7 ms vs
ibuprofen AIX% 23.8, RWT 150.9 ms): adjusted mean
differences AIX% 6.5 (95% CI 1.0 to 11.9; p¼0.02);
RWT  14.2 ms (95% CI  22.2 to  6.3; p¼0.001).
Indomethacin demonstrated an intermediate level of
arterial dysfunction. In relation to arterial dysfunction,
both indomethacin and naproxen were more similar to
diclofenac than to ibuprofen.
Conclusions: ns-NSAID-related AGI is associated with
arterial dysfunction in patients with RA. These ﬁndings
provide a potentially novel insight into the CV toxicity
of commonly used ns-NSAIDs. However, the ﬁndings
are limited by the small number of patients involved
and require further replication in a much larger study.
INTRODUCTION
Non-steroidal anti-inﬂammatory drugs
(NSAIDs) are among the most commonly
prescribed drugs in clinical practice. Their
relative safety has attracted considerable
interest, particularly in relation to their
association with adverse cardiovascular (CV)
events.
1 2 Most of this interest has focused
on the role of selective cyclo-oxygenase-2
(COX-2) inhibitors,
3 but non-selective
NSAIDs (ns-NSAIDs) also have the potential
to increase the risk of adverse CV events. For
example, the use of the ns-NSAID diclofenac
has been shown to increase the risk of
adverse CV events.
2 ns-NSAID use is associ-
ated with adverse CV effects including
reduction in renal perfusion, electrolyte
disturbances (sodium and water retention)
and increase in blood pressure (BP). The
detrimental effects regarding renal function
are thought to be secondary to reduced
synthesis of vasodilatory prostaglandins such
as PGE2. However, ns-NSAIDs have been
shown to exert adverse renal effects dispro-
portionate to the level of inhibition of pros-
taglandin synthesis.
4 This suggests that there
might be other yet unknown mechanisms
responsible for the potential increase in CV
risk associated with ns-NSAID use.
5
Aldosterone metabolism
Very recent in vitro evidence suggests that
ns-NSAIDs enhance the action of aldosterone
through the inhibition of aldosterone
metabolism.
6 Aldosterone is metabolised by
18b-glucuronidation in both the liver and
kidneys in a reaction that is catalysed by the
enzyme UDP-glucuronosyltransferase-2B7.
Several ns-NSAIDs have been shown in vitro
(human kidney cortical microsomes) to
inhibit aldosterone 18b-glucuronidation and
individual NSAIDs vary in their ability to
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Open Access Researchinhibit aldosterone glucuronidation.
6 Diclofenac, for
example, is a strong inhibitor of glucuronidation,
whereas ibuprofen is a weaker inhibitor.
6
Aldosterone is a mineralocorticoid which plays an
important role in the renineangiotensinealdosterone
system and has generally deleterious effects on the CV
system. Higher aldosterone levels are associated with
endothelial dysfunction, arterial stiffening, increased
arterial wall reﬂection, myocardial ﬁbrosis and an
increase in the risk of CV death.
7e10 Drugs that block the
action of aldosterone (such as spironolactone) have
been shown to reduce the risk of CV death in patients
with heart failure and following myocardial infarction.
11
Aldosterone receptors predominate in the aorta and
spironolactone has been shown to improve arterial
function assessed using the technique of pulse wave
analysis (PWA).
7 Consequently, the increased risk of
adverse CV events in patients taking diclofenac may
also be related to the enhanced effects of aldosterone
as a consequence of ns-NSAID-related aldosterone
glucuronidation inhibition (AGI).
RAAIX study
Patients with rheumatoid arthritis (RA) are known to be
at a higher risk of CV death.
12 The RAAIX (RA
Augmentation Index) study was undertaken to assess the
relationship between the cumulative inﬂammatory
burden and arterial dysfunction in patients with RA.
13 14
RAAIX involved a detailed assessment of both CV and
rheumatological features, including assessment of the
use of NSAIDs. Other researchers have subsequently
reported the relative level of aldosterone 18b-glucur-
onidation inhibition (AGI) for several of the ns-NSAIDs
taken by patients in the RAAIX study.
6 In the RAAIX
study, arterial dysfunction was assessed non-invasively
using radial applanation tonometry and PWA.
13 14 PWA
is based on the phenomenon of arterial wave reﬂection
which is inﬂuenced by pulse wave velocity, endothelial
dysfunction, peripheral arterial resistance and left
ventricular ejection.
15 16 In each cardiac cycle, the
outgoing systolic pulse wave is also reﬂected back
towards the heart, predominantly at the level of arterial
bifurcations,
17 and returns to the heart during systole
where it augments the central aortic pressure.
15 16 The
speed of travel of both outgoing and reﬂected waves is
greater in patients with stiffer arteries, which increases
the extent of augmentation (higher AIX%) and reduces
the reﬂected wave transit time (lower RWT).
Study aim
The aim of this exploratory analysis was to assess the
association between ns-NSAID-related AGI and estab-
lished markers of arterial dysfunction using data from
a previous study of patients with RA.
METHODS
In the original study we recruited patients with
a consultant rheumatologist diagnosis of RA by reviewing
the medical records of a consecutive series of patients
attending hospital-based rheumatology clinics in the city
of Aberdeen. We identiﬁed patients 40e65 years of age
with RA of more than 6 months’ duration. While all of
our study participants had a clinical diagnosis of RA
made by a rheumatologist, only 56% (64/114) met
American College of Rheumatology criteria (ACR 4/7)
for RA. We excluded patients with overt arterial disease
(angina, prior myocardial infarction, transient ischaemic
attack, stroke, arterial revascularisation, intermittent
claudication, peripheral arterial disease), atrial ﬁbrilla-
tion, heart failure and valvular heart disease. The
exclusion of patients with arterial disease was based
upon an initial screening patient questionnaire, resting
12-lead ECG (independently reported by a cardiologist
to identify pathological Q-waves, conduction defects,
minor Q-waves associated with ST-segment/T-wave
anomalies) and a detailed medical record review by
a rheumatologist. No participants had a history of recent
ARTICLE SUMMARY
Article focus
- Aldosterone glucuronidation inhibition (AGI) potentiates the
adverse cardiovascular effects of aldosterone.
- Recently published in vivo research suggests that such
inhibition differs between non-selective non-steroidal anti-
inﬂammatory drugs (ns-NSAIDs), with a ranked order of
diclofenac>naproxen>indomethacin>ibuprofen, but no
previous studies have assessed the relationship between ns-
NSAID-related AGI and arterial dysfunction in chronic users.
- This study assessed arterial dysfunction using pulse wave
analysis.
Key messages
- In patients with rheumatoid arthritis we found that chronic use
(>3 months) of diclofenac (high AGI) was associated with
greater arterial dysfunction compared to ibuprofen (lower AGI);
this association was independent of other cardiovascular and
rheumatological factors.
- Indomethacin (intermediate AGI) was associated with an
intermediate level of arterial dysfunction, although naproxen
(intermediate AGI) did not ﬁt the anticipated pattern.
- Our ﬁndings support the concept that AGI may play a role in
the cardiovascular toxicity of some ns-NSAIDs commonly used
in routine clinical practice.
Strengths and limitations of this study
- A single research nurse assessed rheumatoid arthritis patients
who were recruited from a consecutive series attending
a hospital rheumatology clinic. We adjusted for several
important cardiovascular and rheumatological factors known
to be independently associated with arterial function and our
multivariate analysis explained a high proportion of the
variability in arterial dysfunction among chronic ns-NSAID
users. The observational cross-sectional design of our study
means that we cannot assess causation, nor exclude residual
confounding as an explanation for our ﬁndings. The small
number of patients taking each NSAID meant that the
conﬁdence intervals are wide.
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NSAID inhibition of aldosterone metabolisminfection, antibiotic treatment or immunisation within
the previous 2 weeks.
Clinical assessment
Patients attended the Clinical Pharmacology Depart-
ment at Aberdeen Royal Inﬁrmary on a single occasion
and underwent assessment by a single clinical research
nurse (AprileDecember 2006). Assessment took place in
the morning after participants had fasted overnight and
abstained from smoking, alcohol and caffeine. Stand-
ardised assessment included BP measurement, PWA and
fasting venous blood sample (including erythrocyte
sedimentation rate (ESR), rheumatoid factor (RF) and
lipid proﬁle). A self-completed patient questionnaire
included smoking habit and the Stanford Health
Assessment Questionnaire (HAQ).
18 Current medica-
tion use was comprehensively reviewed by the research
nurse and included use of over-the-counter (without the
need for a prescription) NSAIDs. A detailed retrospec-
tive review of the medical records using a previously
piloted study form, was undertaken by a single rheuma-
tologist blinded to all PWA results and included date of
arthritis onset, previous blood test results (ESR, RF),
joint surgery and co-morbidity (including treated
hypertension). Our methods have been described in
detail elsewhere.
13 14 The nurse remained blind to the
patient’s previous medical records (which were not
made available at assessment) and only reviewed current
medication and questionnaire responses (to ensure that
all questionnaires items were fully completed) after PWA
assessment had been completed.
Pulse wave analysis (PWA)
Patients rested supine in a quiet side-room for at least
10 min before undergoing three BP/PWA measure-
ments according to current guidelines.
19 BP was
measured at the right brachial artery using a validated
automatic oscillometric BP machine (Omron HEM757
IntelliSense BP monitor; Omron Healthcare, Bannock-
burn, Illinois, USA).
20 PWA was undertaken using the
SphygmoCor device (AtCor Medical, Sydney, Australia)
with a hand-held tonometer (Millar, Houston, Texas,
USA) applanated at the right radial artery. The Sphyg-
moCor PWA device employs a validated generalised
transfer function to derive the central aortic pulse
waveform from the peripheral waveform.
21 All three
PWA recordings were required to have a in-built Sphyg-
moCor quality index score at least 95% (based on
average pulse height, pulse height variation and diastolic
variation). We have previously demonstrated the
research nurse’s high levels of within-observer and
between-observer repeatability.
22 The research nurse
remained blind to the patient’s previous medical history
until PWA was completed.
Aldosterone glucuronidation inhibition (AGI)
Aldosterone 18b-glucuronidation inhibition constants,
Ki, derived from in vitro studies of human kidney
cortical microsomes (HKCM), have been published for
four of the ns-NSAIDs taken by patients in the RAAIX
study (diclofenac: 8 mM; naproxen: 49 mM; indometh-
acin: 113 mM; ibuprofen: 441 mM; a lower Ki indicates
greater inhibition).
6 Nabumetone is a close structural
analogue of naproxen and the two were combined
together in the analysis.
Statistical analysis
Analysis is based on the mean of the three PWA
measurements. The principle measures of arterial
dysfunction are augmentation index (AIX%) and
reﬂected wave transit time (RWT, ms). Since AIX%
varies with heart rate in an individual, it was standardised
to 75 beats per minute.
23 The UK version of the Stanford
HAQ was scored using standard methods without any
imputation required for missing data.
18 Cumulative ESR-
years were derived from the highest single annual ESR
recorded in the medical record during each year of
follow-up and calculated using the trapezium rule with
linear interpolation when data for a given year were
missing.
24 ESR-years reﬂects both the duration and level
of inﬂammatory burden (eg, 5 years of arthritis and
annual ESRs of 30, 20, 10, 10 and 20 mm/h would
equate to approximately 90 ESR-years). ESR is routinely
measured for almost all RA patients attending the
rheumatology outpatient clinic in Aberdeen, where the
policy is to review all RA patients at least annually.
Complete medical records were available for 112
patients who contributed a total of 1040 person-years of
rheumatoid disease. An annual ESR was available for
77% (797/1040) of these person-years and the avail-
ability of an annual ESR for each year since the onset
of arthritis for individual patients was a median of
93% (IQR 67e100%). The availability of an annual ESR
did not differ by age, gender, RF positivity, RA criteria
(ACR 4/7) or Stanford HAQ disability index (data not
shown).
Multiple linear regression was used to adjust mean
differences in AIX% (and RWT) for variables known to
be associated with AIX%, namely: age, sex, mean arterial
BP, ever smoked, Stanford HAQ disability score and
cumulative ESR-years. Analysis was undertaken using
SPSS v 17. We conﬁrmed that the assumptions of line-
arity, normal distribution and equal variance for
multiple linear regression were met. Goodness of ﬁt
was assessed using the adjusted R
2. The inclusion of
additional variables (study ESR, duration of arthritis,
RA criteria, fasting cholesterol, smoking pack-years,
treated hypertension and current disease-modifying
anti-rheumatic drug (DMARD) use) did not alter
the adjusted values for AIX and RWT reported, nor
improve the goodness of ﬁt of the ﬁnal regression
model.
The study adhered to the principles of the Declaration
of Helsinki and was approved by Grampian Research
Ethics Committee (study reference: 04/S0801/67). All
participants provided informed written consent. The
study was funded from a charitable source (NHS
Grampian Rheumatology Endowments).
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NSAID inhibition of aldosterone metabolismRESULTS
The original study recruited 114 patients. We excluded
nine patients from the analysis who were not currently
taking NSAIDs but had done so within the previous
3 months, and excluded two users of infrequently
prescribed NSAIDs (ketoprofen and tiaprofenic acid).
The characteristics of the remaining 103 patients (82%
female) are shown in table 1.
No patients were taking aspirin or more than one
NSAID concurrently. All NSAID users had been taking
their current NSAID for more than 3 months. Diclofenac
was the most commonly used NSAID and was taken by
almost a third of patients. One quarter of patients had
not taken an NSAID within the previous 3 months
(although 88% of these patients had been prescribed an
NSAID in the past). All patients, both NSAID users and
non-users, had previously received DMARD therapy.
Patient characteristics
NSAID users and non-users were similar regarding age,
sex, waistehip ratio, fasting lipids, glucose, arthritis
duration, age at arthritis onset and previous joint surgery
Table 1 Characteristics of patients with rheumatoid arthritis
Current NSAID use
Yes (n[78) No (n[25)
Cardiovascular features
Female 64 82% 20 80%
Mean age, years (SD) 53.4 6.9 53.9 5.7
Mean heart rate, beats per minute (SD) 69.7 10.6 64.5 8.6
Mean systolic BP, mm Hg (SD) 126.2 16.9 124.7 12.1
Mean diastolic BP, mm Hg (SD) 82.9 10.0 81.3 7.6
Mean pulse pressure, mm Hg (SD) 35.6 9.1 36.9 7.4
Mean arterial BP, mm Hg (SD) 99.5 12.2 97.8 8.8
Mean fasting cholesterol, mmol/l (SD) 5.3 1.2 5.6 1.1
Mean fasting glucose, mmol/l (SD) 5 0.8 5 0.5
Mean waistehip ratio (SD) 0.85 0.08 0.85 0.08
Ever smoked for 12 months or more 44 56% 17 68%
Treated hypertension 12 15% 7 28%
Bendroﬂumethiazide 10 13% 5 20%
Atenolol 6 8% 5 20%
Calcium channel blocker 3 4% 1 4%
ACE inhibitor 2 3% 3 12%
Rheumatological features
Mean age at onset of arthritis, years (SD) 41.8 10.4 41.4 12.1
Median duration of arthritis, years (IQR) 9 4e15 8 4e16
Median Stanford HAQ disability (IQR) 1.4 0.6e1.9 0.6 0.3e1.3
Median study ESR, mm/h (IQR) 19 8e30 10 6e18
Median cumulative ESR-years (IQR) 206 99e468 93 58e297
Rheumatoid factor positive ($30 IU/ml) 66 85% 18 72%
Rheumatoid arthritis criteria (ACR 4/7) 47 60% 10 40%
Previous joint surgery 17 22% 4 16%
Current DMARD therapy 70 90% 24 96%
Current prednisolone therapy 8 10% 3 12%
Current NSAID therapy (>3 months) 78 100% 0 0%
Diclofenac 31 40% ee
Naproxen/nabumetone 16 21% ee
Celecoxib/etoricoxib 11 14% ee
Ibuprofen 7 9% ee
Meloxicam 7 9% ee
Indomethacin 6 8% ee
Other (ketoprofen, tiaprofenic acid) 2 3%
Current cytokine therapy 4 5% 1 4%
Proton pump inhibitor 27 35% 4 16%
Misoprostol 6 8% 0 0%
Central arterial function
Mean augmentation index, AIX% (SD) 31.9 7.9 30.9 8.3
Mean reﬂected wave transit time, ms (SD) 135.7 11.4 133.1 12.4
Figures are numbers (%) unless otherwise indicated.
ACR, American College of Rheumatology; BP, blood pressure, DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte
sedimentation rate; HAQ, Health Assessment Questionnaire; IQR, inter-quartile range; NSAID, non-steroidal anti-inﬂammatory drug.
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users had a slightly lower 10-year predicted risk of a CV
event compared to non-users (median 6% vs 8%;
ManneWhitney U test, p¼0.38).
25 NSAID users had
a higher brachial BP at assessment, lower prevalence of
treated hypertension and lower exposure to tobacco.
The level of current inﬂammation (study ESR), cumu-
lative inﬂammation (ESR-years) and arthritis related
disability (Stanford HAQ) were higher in current
NSAID users. The use of proton pump inhibitors and
misoprostol was also higher among current NSAID users.
The current use of prednisolone and DMARD was
similar for both groups; the overall use of cytokines was
relatively low. The rheumatological and CV features of
ns-NSAID users (with NSAIDs ordered by their level of
AGI) are shown in table 2.
Differences in arterial function
Increasing levels of ns-NSAID-related AGI were associ-
ated with a higher AIX% and a lower RWT (ﬁgure 1).
Mean differences in arterial function between patients
taking diclofenac and the other three ns-NSAIDs
(naproxen, indomethacin, ibuprofen) are shown in
table 3. Diclofenac was selected as the reference group as
it has the highest level of in vitro AGI and was also the
most commonly used ns-NSAID. Compared to the
Table 2 Patient characteristics and use of non-selective non-steroidal anti-inﬂammatory drugs
Aldosterone 18b-
glucuronidation inhibition
constant (Ki), mM
Diclofenac
(n[31)
Naproxen
(n[16)
Indomethacin
(n[6)
Ibuprofen
(n[7)
Ki[8K i [49 Ki[113 Ki[441
Cardiovascular features
Female 28 90% 12 75% 5 83% 5 71%
Mean age, years (SD) 54 6.5 55 5.6 57 5.9 50 9.5
Mean heart rate, beats
per minute (SD)
70.7 11.9 73.0 10.5 68.9 4.6 70.0 10.9
Mean systolic BP,
mm Hg (SD)
126 17.6 125 20.3 118 14.0 123 13.4
Mean diastolic BP,
mm Hg (SD)
83 9.9 82 12.1 75 7.4 84 7.9
Mean pulse pressure,
mm Hg (SD)
35.3 10.5 35.3 9.0 34.4 6.1 31.1 8.1
Mean arterial BP,
mm Hg (SD)
99 12.2 99 15.3 92 9.8 100 10.3
Mean fasting cholesterol,
mmol/l (SD)
5.4 1.3 5.4 1.5 5.8 0.9 5.1 1.0
Mean fasting glucose,
mmol/l (SD)
4.9 1.0 5.1 0.6 5.0 0.4 4.9 0.5
Mean waistehip ratio (SD) 0.85 0.08 0.86 0.09 0.89 0.08 0.88 0.09
Ever smoked for 12 months
or more
17 55% 9 60% 4 67% 3 43%
Treated hypertension 7 23% 3 19% 2 33% 0 0%
Rheumatological features
Mean age at onset of
arthritis, years (SD)
43 11.2 42 8.4 39 7.1 37 11.9
Median duration of
arthritis, years (IQR)
93 e15 10 2e17 19 11e22 11 7e20
Median Stanford HAQ (IQR) 1.4 0.8e2.0 1.6 1.2e1.9 1.5 0.9e1.9 0.6 0.0e1.9
Median ESR-years (IQR) 221 99e526 186 77e435 706 140e825 315 81e829
Rheumatoid factor
positive ($30 IU/ml)
26 84% 13 81% 6 100% 7 100%
Rheumatoid arthritis
criteria (ACR 4/7)
14 45% 11 69% 4 67% 5 71%
Previous joint surgery 9 29% 4 25% 1 20% 2 29%
Current DMARD therapy 28 90% 15 94% 5 83% 6 86%
Central arterial function
Mean augmentation index,
AIX% (SD)
32.3 7.1 34.0 7.3 30.7 3.6 23.8 14.1
Mean reﬂected wave
transit time, ms (SD)
132.7 7.3 134.5 12.6 136.4 8.7 150.9 18.0
Figures are numbers (%) unless otherwise indicated.
ACR, American College of Rheumatology; BP, blood pressure; DMARD, disease modifying anti-rheumatic drug; ESR, erythrocyte
sedimentation rate; HAQ, Health Assessment Questionnaire; IQR, inter-quartile range.
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and rheumatological factors reduced the differences
between ns-NSAIDs, but the observed trend of a higher
degree of arterial dysfunction (higher AIX% and lower
RWT) being associated with increasing levels of
ns-NSAID-related AGI persisted. The exception to this
pattern was the slightly higher AIX% for naproxen
compared to diclofenac. The differences between
ibuprofen and diclofenac reached statistical signiﬁcance
(AIX% 6.5, 95% CI 1.0 to 11.9, p¼0.02; and RWT
 14.2 ms, 95% CI  22.2 to  6.3, p¼0.001), although
only seven patients were chronic users of ibuprofen.
The differences between diclofenac and the two other
ns-NSAIDs (indomethacin and naproxen) were not
statistically signiﬁcant.
Patients with no NSAID use over the previous
3 months (n¼25) had a mean AIX% of 30.9 (SD 8.3)
and a mean RWT of 133.1 (SD 12.5) ms. On adjusted
comparison with current NSAID users (all NSAIDs listed
in table 1 combined), AIX% was  1.0 (95% CI  3.9 to
1.9; p¼0.49) lower and RTW 4.3 ms (95% CI  0.6 to 9.2;
p¼0.09) higher among non-current users. The use
indomethacin was associated with a similar level of
dysfunction (AIX%) compared to patients not currently
taking an NSAID. Interestingly, the use of ibuprofen was
associated with a lower level of AIX% compared to non-
current users (unadjusted mean difference in AIX% 7.1,
95% CI  1.4 to 25.6).
Eleven patients were currently taking a selective
COX-2 inhibitor (eight celecoxib, three etoricoxib) and
had a mean AIX% of 33.6 (SD 6.4) and a mean RWT
of 132.8 (SD 8.8) ms. On adjusted comparison with
diclofenac, AIX% was non-signiﬁcantly higher for
patients taking a selective COX-2 inhibitor (2.9, 95%
CI  1.4 to 6.8; p¼0.19), whereas mean RWT was similar
(adjusted difference  0.7 ms, 95% CI  6.7 to 5.4;
p¼0.80). Brachial BP (135/86 vs 125/82 mm Hg) and
pulse pressure (47 vs 33 mm Hg) were higher for
patients taking a selective COX-2 inhibitor compared to
diclofenac.
DISCUSSION
In summary, we found that the current use of an
ns-NSAID with a higher level of AGI (in vitro AGI) in
patients with RA, appears to be associated with a higher
level of arterial dysfunction. Arterial dysfunction was
highest in patients taking diclofenac (high AGI) and
lowest in those taking ibuprofen (low AGI); differences
Figure 1 Use of non-steroidal anti-inﬂammatory drug
(NSAIDs) and central arterial function in patients with
rheumatoid arthritis.
Table 3 Differences in central arterial function associated with the use of non-selective non-steroidal anti-inﬂammatory drugs
Unadjusted mean
difference (95% CI) p Value
Adjusted mean
difference (95% CI) p Value
Summary of model
R Adj R
2
p Value
(ANOVA)
Augmentation index (AIX%)
Diclofenac Reference group
Naproxen/nabumetone 1.7 ( 2.8 to 6.1) 0.46 1.7 ( 2.0 to 5.4) 0.35 0.70 0.40 0.0003
Indomethacin  1.6 ( 7.7 to 4.5) 0.59  1.0 ( 7.8 to 5.8) 0.77 0.65 0.28 0.02
Ibuprofen  8.6 ( 15.9 to  1.2) 0.02  6.5 ( 11.9 to  1.0) 0.02 0.86 0.67 0.000001
Reﬂected wave transit (RWT), ms
Diclofenac Reference group
Naproxen/nabumetone 1.9 ( 3.9 to 7.7) 0.52 1.3 ( 4.5 to 7.0) 0.66 0.54 0.16 0.05
Indomethacin 3.8 ( 3.0 to 10.6) 0.26 3.5 ( 4.8 to 11.7) 0.40 0.56 0.14 0.13
Ibuprofen 18.2 (9.8 to 26.6) 0.0001 14.2 (6.3 to 22.2) 0.001 0.82 0.59 0.00001
Adjusted using multiple linear regression (MLR) for age, sex, mean arterial blood pressure, ever smoked, Stanford HAQ score and cumulative
erythrocyte sedimentation rate (ESR)-years.
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important CV and rheumatological features known to
inﬂuence arterial function. Patients using indomethacin
(intermediate AGI) had an intermediate level of arterial
dysfunction, but we were not able to demonstrate an
entirely consistent relationship since naproxen had a
higher AIX% than would be anticipated from its relative
level of in vitro AGI.
Comparison with existing literature
A small number of previous studies have assessed arterial
dysfunction in patients with RA using PWA.
13 26e29 The
difference observed in AIX% in this analysis (of 6.5)
between diclofenac and ibuprofen is of a statistically and
clinically relevant magnitude. It compares, for example,
with a 4.2 point reduction in AIX% associated with
3 months of atorvastatin therapy in patients with RA.
28
At coronary angiography, a 10-point higher AIX% at
baseline is associated with a 27% increased risk of CV
events over 4 years of follow-up; a 10 ms higher RWT is
associated with a 15% reduction in CV events.
30
Published research concerning NSAID-related arterial
dysfunction is currently limited. Only one previous
study has directly assessed the inﬂuence of NSAID use on
AIX%. In 12 patients with RA, 14 days of therapy with
indomethacin (75 mg twice daily) was associated with
a 1.2 (95% CI  2.1 to 4.5) point increase in AIX%.
29 In
a study of men aged >50 years undergoing community-
based screening for abdominal aortic aneurysm in the
UK, the use of an NSAID (75% took either ibuprofen,
diclofenac or indomethacin) was signiﬁcantly associated
with reduced aortic wall distensibility assessed using
M-mode ultrasound.
31
Study strengths and limitations
The strengths of our study are that a single research
nurse undertook high quality PWA in a controlled
environment among individuals with RA recruited from
a consecutive series of patients attending a rheumatology
clinic. Our measurement of the cumulative inﬂamma-
tory burden is a particular strength of our study. The
ESR area under the curve (cumulative ESR-years)
reﬂects both the level and duration of inﬂammatory
burden. Only one previous study investigating the rela-
tionship between arterial dysfunction and inﬂammation
has attempted to assess inﬂammatory burden, but this
was restricted to only the most recent 5 years of rheu-
matology clinic follow-up.
13 We measured and adjusted
for several important CV and rheumatological factors in
our analysis, including factors known to be indepen-
dently associated with arterial function. PWA has previ-
ously been shown to be predictive of CV events in
patients after coronary angiography.
30 Our multivariate
model explained a high proportion of the variability
(60e70%) in arterial dysfunction between patients
taking diclofenac and ibuprofen. The characteristics of
our participants are similar to those of RA patients
receiving outpatient care elsewhere in the UK.
32 The
study prevalence of treated hypertension is lower than
that reported elsewhere and probably relates to the
exclusion of patients with overt arterial disease.
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The main limitation of our study is its cross-sectional
nature which means that we can only assess association
rather than direct causation. Since we did not measure
serum aldosterone and ns-NSAID levels in these patients
with RA, we are unable to directly conﬁrm the previous
in vitro ﬁndings. While in vitro research is particularly
useful for the investigation of biological mechanisms,
such laboratory based ﬁndings may not translate exactly
to the less controlled situation of patients with RA.
The analysis reported is based on data from an existing
study, rather than from a study speciﬁcally designed to
assess the inﬂuence of different NSAIDs on arterial
dysfunction. Our assessment of RA patients included
a relatively small number of patients taking each NSAID
and only seven patients were chronic users of ibuprofen.
The numbers of patients taking individual NSAIDs were
too small to permit a comparison of the association of
low/high-dose NSAIDs with arterial dysfunction. The
relatively small size of our study restricted the number of
potential confounding factors (rheumatological and CV)
that could be included in the multivariate analysis
without running the risk of over-ﬁtting the data, although
the inclusion of additional variables in the multivariate
model, such as treated hypertension, did not improve the
goodness of ﬁt or substantially alter the adjusted values
reported for AIX and RWT. As with all observational
studies, we cannot excluded the possibility of residual
confounding as an explanation for our ﬁndings.
Study implications
The ﬁnding that ns-NSAID-related AGI appears to be
associated with arterial dysfunction in patients with RA
provides a potentially novel insight into the CV toxicity
of commonly used ns-NSAIDs. Our results are prelimi-
nary and require conﬁrmation in larger studies investi-
gating different ns-NSAIDs, serum aldosterone
concentrations and surrogate markers of arterial
dysfunction. Several important questions remain to be
addressed, including whether high/low ns-NSAID
dosage is related to arterial dysfunction and if switching
ns-NSAIDs (from high-AGI to low-AGI) improves arterial
function. If the adverse CV events associated with
ns-NSAID use are due to AGI, then switching to an
alternative lower-AGI ns-NSAID may be an appropriate
option for patients heavily dependant on NSAIDs for
symptomatic relief.
Selective COX-2 inhibitors lack a carboxylic acid
functional group and would not be anticipated to inhibit
aldosterone glucuronidation to the same extent as
diclofenac. It is therefore interesting that chronic users
of selective COX-2 inhibitors and diclofenac had simi-
larly high AIX% values. If AGI is not the explanation for
the relatively high level of arterial dysfunction associated
with selective COX-2 inhibitor use, then alternative
mechanisms must be involved. A recent meta-analysis
suggests that selective COX-2 inhibitors may induce
a greater rise in brachial BP compared with ns-NSAIDs.
34
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NSAID inhibition of aldosterone metabolismThis might account for the relatively high AIX% values
associated with selective COX-2 inhibitor use in our
study, since higher brachial pressures (diastolic, systolic,
mean and pulse) also correlate with a higher AIX%.
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